A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 12/21/2016 |
| Start Date: | October 2010 |
| End Date: | November 2019 |
Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration
The main purpose of this study to evaluate the safety and tolerability of CNTO 2476
administered subretinally (beneath the retina) using the iTrack Model 275 micro catheter in
patients with visual acuity (acuteness or clearness of vision) impairment associated with
the geographic atrophy (GA: partial or complete wasting away of retinal layer below the
retina) manifestation of age-related macular degeneration (AMD: medical condition which
usually affects older adults and results in a loss of vision in the center of the visual
field [the macula] because of damage to the retina).
administered subretinally (beneath the retina) using the iTrack Model 275 micro catheter in
patients with visual acuity (acuteness or clearness of vision) impairment associated with
the geographic atrophy (GA: partial or complete wasting away of retinal layer below the
retina) manifestation of age-related macular degeneration (AMD: medical condition which
usually affects older adults and results in a loss of vision in the center of the visual
field [the macula] because of damage to the retina).
The study is a Phase 1/2a, multicenter, randomized (the study medication is assigned by
chance), single dose, dose escalation, fellow-eye controlled study evaluating the safety and
clinical response of a single, subretinal administration of CNTO 2476 in patients with
visual acuity impairment associated with GA secondary to AMD. The study will consist of
screening (up to 21 days prior to treatment) period, treatment (Day 1) period and follow up
period. The study will be conducted in 2 portions: the Phase 1 portion will include dose
escalation and the Phase 2 portion will enroll additional patients randomized to one of the
2 optimal doses selected from the Phase 1 portion (with an acceptable safety profile seen in
Phase 1). For Phase 1, the treatment eye will be the eye with worse visual acuity or the one
chosen by the investigator, however, the treatment eye cannot have a visual acuity no better
than 20/200. For Phase 2a, the treatment eye will be the eye with worse visual acuity, and
cannot have a visual acuity better than 20/80. Approximately 30 patients will participate in
the Phase 1 dose escalation portion, and 38 patients will be enrolled in the Phase 2a
portion (19 patients receiving optimal dose level X from Phase 1 and 19 receiving optimal
dose level Y from Phase 1). In the Phase 1 portion, treatment will be assigned 5 sequential
cohorts, with 3 patients per cohort in each of the first 4 cohorts and 6 patients in the
fifth cohort. Cohort A patients will be treated first, followed by Cohort B patients. All
patients in a given cohort must have completed at least 4 weeks of post-treatment follow-up
before patients in the next cohort may be treated. Follow-up will include postoperative
follow-up period of 12 months (Day 2, Day 7, Day 15, Week 3, Week 4, Months 2, 3, 6, and 12)
and long-term safety follow-up period of 4 years (patients will be evaluated every 6 months
for safety assessments). Safety assessments will include vital signs, AEs, and concomitant
medications and routine 12-lead electrocardiograms (ECG). The anticipated study duration
will be approximately 5 years (1 year in the 12-month postoperative follow-up period; 4
years in the long-term safety follow-up period).
chance), single dose, dose escalation, fellow-eye controlled study evaluating the safety and
clinical response of a single, subretinal administration of CNTO 2476 in patients with
visual acuity impairment associated with GA secondary to AMD. The study will consist of
screening (up to 21 days prior to treatment) period, treatment (Day 1) period and follow up
period. The study will be conducted in 2 portions: the Phase 1 portion will include dose
escalation and the Phase 2 portion will enroll additional patients randomized to one of the
2 optimal doses selected from the Phase 1 portion (with an acceptable safety profile seen in
Phase 1). For Phase 1, the treatment eye will be the eye with worse visual acuity or the one
chosen by the investigator, however, the treatment eye cannot have a visual acuity no better
than 20/200. For Phase 2a, the treatment eye will be the eye with worse visual acuity, and
cannot have a visual acuity better than 20/80. Approximately 30 patients will participate in
the Phase 1 dose escalation portion, and 38 patients will be enrolled in the Phase 2a
portion (19 patients receiving optimal dose level X from Phase 1 and 19 receiving optimal
dose level Y from Phase 1). In the Phase 1 portion, treatment will be assigned 5 sequential
cohorts, with 3 patients per cohort in each of the first 4 cohorts and 6 patients in the
fifth cohort. Cohort A patients will be treated first, followed by Cohort B patients. All
patients in a given cohort must have completed at least 4 weeks of post-treatment follow-up
before patients in the next cohort may be treated. Follow-up will include postoperative
follow-up period of 12 months (Day 2, Day 7, Day 15, Week 3, Week 4, Months 2, 3, 6, and 12)
and long-term safety follow-up period of 4 years (patients will be evaluated every 6 months
for safety assessments). Safety assessments will include vital signs, AEs, and concomitant
medications and routine 12-lead electrocardiograms (ECG). The anticipated study duration
will be approximately 5 years (1 year in the 12-month postoperative follow-up period; 4
years in the long-term safety follow-up period).
Inclusion Criteria:
- Women must be incapable of childbearing
- Patient must be a suitable candidate for ophthalmologic surgery, is willing and able
to comply with the surgical procedure, scheduled visits, treatment plan, laboratory
tests and other study procedures
- Confirmed diagnosis of bilateral geographic atrophy (GA) of the macula bilaterally
caused by age-related macular degeneration
Exclusion Criteria:
- Evidence of exudative ("wet") age -related macular degeneration in either eye
- Evidence of other significant ophthalmologic disease (eg, glaucoma)
- Ocular hypertension
- Previous cell therapy other than blood components
- Previous treatment for age-related macular degeneration (AMD) other than antioxidant
or zinc supplements or other oral vitamin supplements
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials